


More than
30%
of Sarah Cannon
clinical trials require the
results of a molecular
profiling test



More than
85%
of cancer patients
are treated in
the community
setting



2,000+
Patients treated
per year on clinical
trials across Sarah
Cannon



275+
Physicians
who engage in
research across our
strategic sites

Personalized Medicine

Sarah Cannon Personalized Medicine Program

The Sarah Cannon Personalized Medicine Program was initiated in 2012 and operates in programs across the U.S. and UK. Working with best-in-class commercial laboratory service providers, we have access to thousands of patients across tumor types to rapidly identify eligible patients for early and late-phase clinical trials and approved targeted therapies.

Provide scientific insight to community oncologists across the U.S. and the UK.

Promote patient access to targeted therapies and clinical trials

Transform care by personalizing treatment

Our Approach

Sarah Cannon's genomics portal integrates molecular data into the clinical workflow, tailors clinical decisions and extends expertise to affiliate networks.

Sarah Cannon's Personalized Medicine team provides scientific insight to community oncologists on:

- Who and when to profile
- How to order molecular profiling tests
- How to interpret molecular profiling results
- Which targeted therapy/clinical trial is appropriate for individual patients
- Tracking progress across patient populations